QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
NASDAQ:RLYB

Rallybio - RLYB Stock Forecast, Price & News

$4.86
+0.08 (+1.67%)
(As of 12/9/2022 01:46 PM ET)
Add
Compare
Today's Range
$4.80
$5.76
50-Day Range
$4.76
$14.86
52-Week Range
$4.57
$15.89
Volume
3,390 shs
Average Volume
163,923 shs
Market Capitalization
$155.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

Rallybio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
434.0% Upside
$27.50 Price Target
Short Interest
Bearish
5.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Rallybio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.28) to ($2.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

550th out of 1,022 stocks

Pharmaceutical Preparations Industry

247th out of 499 stocks

RLYB stock logo

About Rallybio (NASDAQ:RLYB) Stock

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

RLYB Stock News Headlines

Rallybio Announces Pricing of $50 Million Public Offering
Rallybio Announces Proposed Public Offering
Rallybio Reports Third Quarter 2022 Financial Results
Rallybio Corporation (RLYB)
Rallybio Reports Second Quarter 2022 Financial Results
See More Headlines
Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

RLYB Company Calendar

Last Earnings
11/10/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RLYB
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.50
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+599.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-47,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.47 per share

Miscellaneous

Free Float
29,536,000
Market Cap
$155.67 million
Optionable
Not Optionable
Beta
-2.08

Key Executives

  • Dr. Martin W. MacKay Ph.D. (Age 66)
    Co-Founder, CEO & Chairman
    Comp: $625.37k
  • Dr. Stephen Uden M.B (Age 64)
    M.D., Co- Founder, Pres, COO & Chief Scientific Officer
    Comp: $625.37k
  • Mr. Jeffrey M. Fryer CPAMr. Jeffrey M. Fryer CPA (Age 52)
    Co-Founder, CFO & Treasurer
    Comp: $625.37k
  • Ms. Ami Bavishi
    Head of Investor Relations & Corp. Communications
  • Dr. Steven W. Ryder F.A.C.P (Age 71)
    M.D., Chief Medical Officer













RLYB Stock - Frequently Asked Questions

Should I buy or sell Rallybio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RLYB shares.
View RLYB analyst ratings
or view top-rated stocks.

What is Rallybio's stock price forecast for 2023?

2 equities research analysts have issued 12 month price objectives for Rallybio's shares. Their RLYB share price forecasts range from $21.00 to $34.00. On average, they expect the company's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 465.8% from the stock's current price.
View analysts price targets for RLYB
or view top-rated stocks among Wall Street analysts.

How have RLYB shares performed in 2022?

Rallybio's stock was trading at $9.54 at the beginning of the year. Since then, RLYB stock has decreased by 49.1% and is now trading at $4.86.
View the best growth stocks for 2022 here
.

When is Rallybio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our RLYB earnings forecast
.

How were Rallybio's earnings last quarter?

Rallybio Co. (NASDAQ:RLYB) issued its earnings results on Wednesday, November, 10th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.52.

When did Rallybio IPO?

(RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share.

What is Rallybio's stock symbol?

Rallybio trades on the NASDAQ under the ticker symbol "RLYB."

Who are Rallybio's major shareholders?

Rallybio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Tekla Capital Management LLC (5.42%), BlackRock Inc. (3.08%), Vanguard Group Inc. (2.49%), State Street Corp (0.79%), Dimensional Fund Advisors LP (0.07%) and Nuveen Asset Management LLC (0.07%). Insiders that own company stock include Jeffrey M Fryer, Kush Parmar, Martin Mackay, Opportunities I LP 5Am and Stephen Uden.
View institutional ownership trends
.

How do I buy shares of Rallybio?

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rallybio's stock price today?

One share of RLYB stock can currently be purchased for approximately $4.86.

How much money does Rallybio make?

Rallybio (NASDAQ:RLYB) has a market capitalization of $155.67 million. The company earns $-47,010,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis.

How can I contact Rallybio?

The official website for the company is www.rallybio.com. The company can be reached via phone at 203-859-3820 or via email at investors@rallybio.com.

This page (NASDAQ:RLYB) was last updated on 12/9/2022 by MarketBeat.com Staff